ISSN: 0172-780X | ISSN-L: 0172-780X | eISSN 2354-4716

www.nel.edu Editor-in-Chief: Peter G. Fedor-Freybergh

Editorial.

Fedor-Freybergh P.

Editorial 2002; 23(4): 271-272 PubMed PMID: 12195223 Keywords: Humans, Neuroendocrinology:trends, Periodicals as Topic:trends,.

Similar articles

Progression of the erectile dysfunction in the population and the possibilities of its regression with bioregeneration.

Wendlova J.

Editorial

2013; 34(6): 482-497

PubMed PMID: 24378458

Citation

Citation

Wendlova J. Progression of the erectile dysfunction in the population and the possibilities of its regression with bioregeneration. Neuro Endocrinol Lett. 2013 Jan; 34(6): 482-497

Physiotherapy as an immunoactive therapy? A pilot study.

Rasova K, Dolezil D, Kalistova H, Kucera P, Juzova O, Zimova D, Medova E, Jandova D, Tintera J, Ibrahim I, Zvara K, Bicikova M, Martinkova P.

Editorial

2012; 33(1): 67-75

PubMed PMID: 22467115

Citation

Citation

Rasova K, Dolezil D, Kalistova H, Kucera P, Juzova O, Zimova D, Medova E, Jandova D, Tintera J, Ibrahim I, Zvara K, Bicikova M, Martinkova P. Physiotherapy as an immunoactive therapy? A pilot study. Neuro Endocrinol Lett. 2012 Jan; 33(1): 67-75

Stress hormones predict hyperbolic time-discount rates six months later in adults.

Takahashi T, Shinada M, Inukai K, Tanida S, Takahashi C, Mifune N, Takagishi H, Horita Y, Hashimoto H, Yokota K, Kameda T, Yamagishi T.

Editorial

2010; 31(5): 616-621

PubMed PMID: 21178944

Citation

Citation

Takahashi T, Shinada M, Inukai K, Tanida S, Takahashi C, Mifune N, Takagishi H, Horita Y, Hashimoto H, Yokota K, Kameda T, Yamagishi T. Stress hormones predict hyperbolic time-discount rates six months later in adults. Neuro Endocrinol Lett. 2010 Jan; 31(5): 616-621

Maintenance treatment of bipolar disorders.

Rybakowski J.

Editorial

2005; 26(Suppl 1): 49-65

PubMed PMID: 16361988

Citation

Citation

Rybakowski J. Maintenance treatment of bipolar disorders. Neuro Endocrinol Lett. 2005 Aug; 26(Suppl 1): 49-65

A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.

Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.

Editorial

2002; 23(3): 255-258

PubMed PMID: 12080288

Citation

Citation

Lissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G. A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone. Neuro Endocrinol Lett. 2002 Jun; 23(3): 255-258